Utilization of PROMIS Neuropathic Pain Quality for Detection and Monitoring Neuropathic Pain in Heel Pain Patients
Open Access
- 1 October 2023
- journal article
- research article
- Published by SAGE Publications in Foot & Ankle Orthopaedics
- Vol. 8 (4)
Abstract
Background: Diagnosis and management of neuropathic pain (NP) in foot and ankle patients remain challenging. We investigated the plausibility of using Patient-Reported Outcomes Measurement Information System (PROMIS) Neuropathic Pain Quality (PQ-Neuro) as an initial screening tool to detect NP and track the treatment effects. Methods: Patients with heel pain were prospectively recruited and grouped to no-NP, mild-NP, and severe-NP based on the initial PROMIS PQ-Neuro t scores. Pain Interference (PI), Physical Function (PF), and Self-Efficacy (SE) scores were evaluated at baseline, 30-day, and 90-day follow-up. Other factors such as age, smoking, body mass index (BMI), low back/neck pain, anxiety/depression, and medications were analyzed. Linear mixed modeling was used to assess the main effects of time and NP on PROMIS t scores, comparing minimal clinically important difference (MCID). Results: Forty-eight patients with mean age of 52.4 years were recruited. Using the PROMIS PQ-Neuro as the assessment tool, 33 patients (69%) were detected to have NP at baseline—23 (48%) mild and 10 (21%) severe. BMI was the only independent factor associated with NP ( P = .011). Higher baseline PQ-Neuro t score was significantly associated with higher follow-up PQ-Neuro ( P < .001), PI ( P = .005), and lower SE ( P = .04) across time points. Patients with NP showed lower PF at baseline with significantly less improvement in PF (3 vs 9.9, P = .035) and did not meet MCID. Conclusion: Baseline PROMIS PQ-Neuro ≥46 was significantly associated with worse PI and SE across all time points, with less clinically significant improvements in PF. Prevalence of NP in heel pain patients was high. The PROMIS PQ-Neuro may serve as a valuable tool for detection of NP and guiding clinical treatment decision pathways for heel pain patients. Level of Evidence: Level III, prospective cohort study.Keywords
This publication has 28 references indexed in Scilit:
- The PROMIS Physical Function item bank was calibrated to a standardized metric and shown to improve measurement efficiencyJournal of Clinical Epidemiology, 2014
- Neuropathic pain in the general population: A systematic review of epidemiological studiesPain, 2014
- Painful Diabetic PolyneuropathyThe Clinical Journal of Pain, 2012
- The Pain Quality Response Profile of Pregabalin in the Treatment of Neuropathic PainThe Clinical Journal of Pain, 2012
- A 12-Year Long-Term Retrospective Analysis of the Use of Radiofrequency Nerve Ablation for the Treatment of Neurogenic Heel PainFoot & Ankle Specialist, 2010
- Development of a PROMIS item bank to measure pain interferencePain, 2010
- Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomesJournal of Clinical Epidemiology, 2008
- A Review of the Epidemiology of Painful Diabetic Peripheral Neuropathy, Postherpetic Neuralgia, and Less Commonly Studied Neuropathic Pain ConditionsPain Practice, 2008
- Development and testing of a neuropathic pain screening questionnaire: ID PainCurrent Medical Research and Opinion, 2006
- Assessment of pain quality in chronic neuropathic and nociceptive pain clinical trials with the Neuropathic Pain ScaleThe Journal of Pain, 2005